Clinical Study
The Role of Simvastatin in the Therapeutic Approach of Rheumatoid Arthritis
Table 2
Differences after 3 and 6 months of treatment.
| Variable | Follow-up visit | Simvastatin group | Control group | |
| Early morning stiffness (min) | 3 month | | | 0.63 | 6 month | | | 0.996 | Tender joint count | 3 month | | | 0.03 | 6 month | | | 0.243 | Swollen joint count | 3 month | | | 0.068 | 6 month | | | 0.288 | VAS pain (mm) | 3 month | | | 0.888 | 6 month | | | 0.481 | Patient global assessment (mm) | 3 month | | | 0.273 | 6 month | | | 0.196 | Evaluator global assessment (mm) | 3 month | | | <0.001 | 6 month | | | 0.007 | HAQ-DI | 3 month | | | 0.353 | 6 month | | | 0.149 | Erythrocyte sedimentation rate (mm/h) | 3 month | | | 0.203 | 6 month | | | 0.751 | C-reactive protein (mg/L) | 3 month | | | 0.055 | 6 month | | | 0.687 | DAS28 ESR | 3 month | | | 0.009 | 6 month | | | 0.171 | DAS28 CRP | 3 month | | | 0.02 | 6 month | | | 0.151 | SDAI | 3 month | | | 0.003 | 6 month | | | 0.067 | CDAI | 3 month | | | 0.004 | 6 month | | | 0.068 | EULAR response | 3 month | 16 (32%) | 7 (14%) | 0.033 | 6 month | 15 (30%) | 11 (22%) | 0.364 | Attendance to visit | 3 month | 48 (96%) | 49 (98%) | 0.560 | 6 month | 45 (90%) | 43 (86%) | 0.540 |
|
|
Between the breaks, there are 95% confidence interval or percents.
|